A new peer-reviewed study has quietly revealed one of the most consequential biological findings of the pandemic era — and the authors never acknowledge it: Every single vaccinated participant in the study had fibrinolysis-resistant, ThT-positive amyloid microclots circulating in their blood.

Hidden in the supplementary tables is a demographic and biochemical pattern that completely reframes the paper:

94% of all participants were vaccinated.
100% of these vaccinated individuals had amyloid microclots — including every “healthy control.”

The condition labeled “Long COVID” occurred almost entirely in a heavily vaccinated population, without any laboratory confirmation of prior SARS-CoV-2 infection. In reality, the study is observing Long VACCINE pathology, not Long COVID.

And because the authors’ own mechanistic experiments show that purified spike protein alone produces these amyloid, fibrinolysis-resistant clots, the implications are profound.

All individuals in the study — 100% of the vaccinated — had amyloid microclots

Researchers identified microclots using Thioflavin-T (ThT), an amyloid-binding fluorogenic dye. ThT positivity was the defining criterion. A structure was only counted as a microclot if it bound ThT.

Therefore, every microclot counted in the study is, by definition, amyloidogenic.

And according to Table S11, every single vaccinated participant had amyloid microclots in multiple size ranges:

Because 83 of 88 participants (94%) were vaccinated, this means:

Every vaccinated person in the study had amyloid microclots.

“Long COVID” (Long VACCINE) patients had extreme elevations in large, pathological amyloid microclots

Small amyloid microclots were present in everyone, but the pathological burden differed sharply.

According to Table S11:

• 98% of “Long COVID” (Long VACCINE) patients had large microclots in the 900–1600 µm² range
• 60% had very large microclots >1600 µm²
• Total microclot burden was ~20-fold higher in “Long COVID” patients

These larger, pathogenic amyloid microclots were densely packed with:

• Neutrophil extracellular traps (NETs)
• Myeloperoxidase
• Neutrophil elastase
• Extracellular DNA
• Misfolded amyloid fibrin

COVID-19 infection was never verified

Despite positioning the results as a hallmark of “Long COVID,” none of the participants were confirmed to have had SARS-CoV-2 infection. The study performed:

• no antibody testing
• no PCR
• no sequencing
• no neutralizing antibody assays

Long COVID status was assigned purely via symptoms and clinician impression. There is no evidence in the study that any participant was biologically positive for prior infection.

Thus, the clotting abnormalities cannot be attributed specifically to infection, but rather to vaccination.

Spike protein alone produced identical amyloid microclots

In a mechanistic experiment, the authors added purified spike protein to fibrinogen.

This single intervention produced:

• insoluble, ThT-positive amyloid microclots
• misfolded fibrin structures identical to those in patient samples
• fibrinolysis-resistant aggregates compatible with vessel obstruction

The authors confirmed that Spike protein directly induces amyloid microclot formation, corroborating previous studies.

Explains prevalent white fibrous clots found in the dead

The study’s core findings — 100% amyloid microclots in vaccinated individuals and direct spike-induced amyloid fibrin formation — offer a clear mechanism for the large, rubbery white fibrous clots increasingly reported in deceased individuals since 2021.

At the 2025 Tennessee Funeral Directors Association (TFDA) convention, former USAF Major Tom Haviland conducted the first state-level survey of embalmers:

• 64% reported white fibrous clots in 2025
• Found in 17% of all bodies
• 70% observed widespread microclotting (“coffee-grounds blood”)
• 39% reported rising infant deaths (+14%)

Forensic analysis by Kevin W. McCairn, PhD et al shows that these postmortem clots:

• are amyloidogenic fibrin aggregates, not normal thrombi
• exhibit β-sheet structures (ThT-positive)
• are protease-resistant, rubbery, and fibrous
• have dense fibrillar ultrastructure on SEM
• contain human genetic material
• and show preliminary plasmid/spike-associated markers

These characteristics match exactly the pathological microclots described in the new study — only at a later, aggregated, end-stage form.

The progression is biologically straightforward:

1. Spike exposure (infection or mRNA vaccination)
2. Amyloid microclots form — present in 100% of vaccinated subjects
3. Large, NET-rich, fibrinolysis-resistant clots accumulate (20× higher in Long vaccine patients)
4. These merge into massive, rubbery, white fibrous intravascular clots

This new study documents the early and intermediate stages in the living; Haviland’s surveys and McCairn’s analysis reveals the final stage in the dead.

Conclusions

Although the authors frame their findings as “Long COVID,” the underlying data reveal something far more consequential:

• 100% of vaccinated participants had amyloid microclots.
• Large, fibrinolysis-resistant amyloid microclots were concentrated in the Long vaccine group.
• No participant had laboratory-confirmed SARS-CoV-2 infection.
• Spike protein alone produced identical amyloid microclots in vitro.
• With 94% vaccination uptake, the biological signal is overwhelmingly linked to spike exposure in a vaccinated population.

These findings carry serious public-health implications:

• Every vaccinated individual in the study showed early-stage amyloid microclots, raising alarms about cumulative vascular injury across the entire globe.
• The pathology mirrors the large white fibrous clots now documented by embalmers and forensic analysts.

And critically:

• The CDC and federal public-health agencies must finally do their job and launch an immediate, transparent investigation into these findings.

• Failing to intestigate the white fibrous clot situation constitutes a dereliction of duty.

• Any platform delivering spike protein into human circulation must be immediately banned for human use.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

Support our mission: mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content.

Source

************